[Temporary Announcement] Huayi Taikang: Indicative Announcement Regarding the Board of Directors’ Consideration of the Proposal for Public Issuance of Shares and Listing on the Beijing Stock Exchange
Announcement number: 2026-005
Securities code: 874191 Securities abbreviation: Huayi Taikang Sponsoring broker: Guolian Minsheng Underwriting and Sponsor
Huayitaikang Pharmaceutical Co., Ltd.
Indicative announcement regarding the Board of Directors’ consideration of the proposal for public issuance of shares and listing on the Beijing Stock Exchange
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Basic situation
The company held the 13th meeting of the second board of directors on January 21, 2026, and reviewed and approved the "Proposal on the Company's Application for Public Issuance of Stocks and Listing on the Beijing Stock Exchange" and other related proposals. This proposal still needs to be submitted to the company's shareholders' meeting for review.
(1) Types of stocks issued this time:
RMB ordinary shares.
(2) Par value of issued shares:
The par value per share is 1 yuan.
(3) Number of shares issued this time:
The company plans to publicly issue no more than 20,016,000 shares to unspecified qualified investors (including the principal number, without considering the over-allotment option), and the shareholding ratio of public shareholders after the issuance will not be less than 25% of the company's total share capital. The company and the lead underwriter will choose an opportunity to use the over-allotment option based on the specific issuance conditions. The number of shares issued using the over-allotment option will not exceed 15% of the number of shares issued this time, that is, no more than 3,002,400 shares (including the principal number). Including the number of shares issued using the over-allotment option, the number of shares issued this time will not exceed 23,018,400 shares (including the principal number).
(4) Pricing method:
The issuance price is determined through independent negotiation between the issuer and the lead underwriter, such as direct pricing, online bidding by qualified investors, or offline price inquiry. The final pricing method will be determined by the board of directors authorized by the shareholders' meeting to negotiate with the lead underwriter based on specific circumstances and regulatory requirements.
(5) Issuance floor price:
Announcement number: 2026-005
The subsequent inquiry or pricing results will be used as the issuance floor price.
(6) Scope of issuance objects:
Qualified investors who have opened the trading authority for stocks of listed companies on the Beijing Stock Exchange, except those prohibited from subscription by laws, regulations and normative documents.
(7) Purpose of raised funds:
In order to further enhance the company's core competitiveness and promote the company's sustainable development, in accordance with the requirements of relevant securities laws and regulations and in conjunction with the company's actual situation, the net amount of funds raised by the company after deducting issuance expenses will be fully invested in the following projects:
Total project investment Amount of raised funds investment Serial number Project name
(10,000 yuan) (10,000 yuan)
Huayitaikang Pharmaceutical Intelligence
Energy manufacturing and innovation research
1 37,241.70 30,000.00
Development headquarters base construction
Project (Phase I)
After the raised funds are in place, if the actual net amount of raised funds is less than the amount of raised funds planned to be used for the above projects, the shortfall in raised funds will be raised by the company itself. If the net amount of funds raised this time exceeds the amount of funds to be used for the above-mentioned projects, the company will manage and use the excess funds in strict accordance with the relevant regulations of the regulatory agency. Before the funds raised are in place, if the company invests in the raised investment project with self-raised funds based on its operating conditions and development plan, the part of the advance investment will be replaced with the part that complies with laws, regulations and relevant requirements of the China Securities Regulatory Commission after the funds raised in this issuance are in place.
(8) Distribution plan for accumulated profits before issuance:
After this issuance, the undistributed profits accumulated before the issuance will be shared by the new and old shareholders of the company according to the proportion of their shares in the company after the issuance.
(9) Relevant arrangements for stock listing after the issuance is completed:
After the issuance is completed, the company's shares will be listed on the Beijing Stock Exchange, and the company's shares will cease to be listed on the National Equities Exchange and Quotations on the day of listing.
(10) Resolution validity period:
It is valid for 12 months from the date of approval by the shareholders' meeting. If the company obtains the approval of the China Securities Regulatory Commission to register for this issuance within this validity period, the validity period of this authorization will be automatically extended to this public issuance and listing.
Announcement number: 2026-005
Date of completion.
(11) Description of other matters:
Strategic allotment: Based on the needs of the financing scale, the company may implement strategic allotment during this issuance and allocate part of the stock to investors who meet the requirements of laws and regulations and the company's development strategy. The final issuance number will be determined by the board of directors in consultation with the lead underwriter based on the authorization of the shareholders' meeting and on a case-by-case basis.
Underwriting method: This issuance is underwritten by the lead underwriter on a balance underwriting basis.
The final issuance plan shall be subject to the plan approved by the Beijing Stock Exchange and approved by the China Securities Regulatory Commission for registration.
2. Risk warning
The company's application for a public issuance of shares and listing on the Beijing Stock Exchange carries the risk of failing to pass the issuance and listing review of the Beijing Stock Exchange or registration with the China Securities Regulatory Commission. The company faces the risk of being unable to be listed on the Beijing Stock Exchange due to a failed public offering.
The company's audited net profits attributable to shareholders of the listed company in 2023 and 2024 (whichever is lower before and after deducting non-recurring gains and losses) are 39.8681 million yuan and 53.7929 million yuan respectively, and the weighted average return on net assets (whichever is lower before and after deducting non-recurring gains and losses) are respectively 21.92%, 18.77%. The listed company meets the conditions for public issuance of stocks stipulated in the "Registration and Management Measures of the Beijing Stock Exchange for the Public Issuance of Stocks to Unspecified Qualified Investors", and there is no situation that prohibits listing on the Beijing Stock Exchange as stipulated in the "Listing Rules".
Investors are advised to pay attention to the risks.
3. Documents for reference
(1) "Resolution of the Thirteenth Meeting of the Second Board of Directors of Huayi Taikang Pharmaceutical Co., Ltd.";
(2) "Independent opinions of the independent directors of Huayi Taikang Pharmaceutical Co., Ltd. on matters related to the 13th meeting of the second board of directors";
(3) "Resolution of the Fourth Meeting of the Audit Committee of the Second Board of Directors of Huayi Taikang Pharmaceutical Co., Ltd."
Board of Directors of Huayitaikang Pharmaceutical Co., Ltd.
January 23, 2026